Specific Recognition of Arginine Methylated Histone Tails by JMJD5 and JMJD7

Haolin Liu1,5,6, Chao Wang1,5, Schuyler Lee1,5, Fangkun Ning1,5, Yang Wang1,5, Qianqian Zhang2, Zhongzhou Chen1,5, Jianye Zang3, Jay Nix4, Shaodong Dai1,5, Philippa Marrack1,5,6, James Hagman1,5, John Kappler1,5,6 & Gongyi Zhang1,5

We have reported that JMJD5 and JMJD7 (JMJD5/7) are responsible for the clipping of arginine methylated histone tails to generate “tailless nucleosomes”, which could release the pausing RNA polymerase II (Pol II) into productive transcription elongation. JMJD5/7 function as endopeptidases that cleave histone tails specifically adjacent to methylated arginine residues and continue to degrade N-terminal residues of histones via their aminopeptidase activity. Here, we report structural and biochemical studies on JMJD5/7 to understand the basis of substrate recognition and catalysis mechanism by this JmjC subfamily. Recognition between these enzymes and histone substrates is specific, which is reflected by the binding data between enzymes and substrates. High structural similarity between JMJD5 and JMJD7 is reflected by the shared common substrates and high binding affinity. However, JMJD5 does not bind to arginine methylated histone tails with additional lysine acetylation while JMJD7 does not bind to arginine methylated histone tails with additional lysine methylation. Furthermore, the complex structures of JMJD5 and arginine derivatives revealed a Tudor domain-like binding pocket to accommodate the methylated sidechain of arginine, but not lysine. There also exists a glutamine close to the catalytic center, which may suggest a unique imidic acid mediated catalytic mechanism for proteolysis by JMJD5/7.

The phenomenon of cleavage at histone tails has been revealed several decades ago1, which is consistent with reports of high turnover rate of histone subunits within non-proliferating cells2. Similarly, arginine methylation on histone tails is very well characterized and a family containing at least 9 arginine methyltransferases has been established3. The reversibility hallmark of epigenetics indicates there must exist an enzyme family responsible for the removal of methyl groups on arginines. To this regard, JMJD6 was first reported to have such ability by two groups4,5. Interestingly, another group claimed that lysine demethylases also contain arginine demethylase activities6. On the other hand, it remains a mystery as to how phosphorylation of CTD of RNA Polymerase II (Pol II) by CDK9 release the pausing Pol II into productive elongation. It was reported that nucleosomes at +1 position is the major barrier to block the Pol II from elongation7. It is still unknown how nucleosomes at +1 are removed during transcription elongation. Our recent discovery revealed that JMJD5 and JMJD7 specifically make first cleavage at methylarginine sites on histone tails through endopeptidase activities and continue to trim histone tails with aminopeptidase activities to generate “tailless nucleosomes”8, which should be overcome by Pol II without further additional assistance, just as that of Archaea bacteria9. We also found that the cleavage activities of both JMJD5 and JMJD7 are essential for proliferation of mice fibroblast cells and breast cancer cells respectively8. Furthermore, both arginine methylated histones and overall histone content are dramatically increased in both JMJD5 and JMJD7 deficient cells, suggesting that both JMJD5 and JMJD7 regulate the homeostasis of histones8. Our data suggest that clipping of histone tails, “tailless nucleosomes” generation, arginine methylation,
The structure of JMJD7. We crystallized multiple versions of mouse JMJD7, including a MBP-JMJD7 fusion protein (with a truncated linker) and a JMJD7 protein alone (generated from GST-JMJD7 fusion protein). The structure of MBP-JMJD7 was determined using the molecular replacement method with both MBP (PDB:1HSJ) and c-JMJD7 (PDB: 4QU1) as starting models (Table S1, Table S2, Table S3). Two molecules of MBP-JMJD7, which form a dimer through two helix bundles (each one is formed by one helix from the N-terminus and another one from the C-terminus), assembled one asymmetric unit with slightly different conformations in the absence of α-KG (Fig. 1, Fig. S1). The structure of the JMJD7 alone version was determined by molecular replacement of the MBP-JMJD7 structure in the presence of α-KG. Again, two molecules of JMJD7, which formed dimers similar to those of the MBP-JMJD7 fusion (suggesting that the dimer is not an artificial one caused by MBP or crystal packing), were observed in one asymmetric unit with slightly different conformations (Fig. 1, Fig. S2). Besides the two helix bundles, additional helices participated in protein-protein interactions (Fig. 1B). This dimeric form may represent a functionally relevant form of the protein in vivo.

Comparing all four JMJD7 structures (two MBP-JMJD7 fusions, two GST-free JMJD7, each with or without α-KG), we found several interesting differences (Fig. 1C). First, marginal conformational changes were detected in the active site with and without α-KG (Fig. 1 and Fig. S2). Second, discrete regions were flexible and adopted variable conformations in different packing environments (red dotted circles in Fig. 1C and difference in surface charge distribution in Fig. S2). Similar to all JmJC domain containing proteins, JMJD7 has the Cupin signature fold at the catalytic core including the Fe^{2+} and α-KG binding site (Fig. 2A). Several unique structural features are worth noting. First, a helix from the N-terminus (α1, colored blue) and another helix from the C-terminus (α11, colored red) form a coil-coil helical bundle, which participates in dimer formation (Fig. 1A). Second, compared to other JmJC domain containing proteins, two extra beta hairpins generated by β3 and β4, and β12 and β13, cross each other to help form the potential substrate binding site (Fig. 1A, Fig. S3). Furthermore, the unique surface charge distribution of JMJD7 suggests that it may accommodate highly charged histone tails (Fig. 2A). A negatively charged catalytic center is surrounded by nearby distribution of positively charged patches, indicating a
preference for positively charged sidechains of methylarginine at the catalytic core, while accommodating neutral or negatively charged neighboring residues on histone tail substrates (Fig. 2A).

Comparisons of JMJD7 to other JmjC proteins. Numerous structures of JmjC protein family members have been determined (Fig. S4), including the lysine hydroxylase FIH27, lysine demethylase JMJD2A28,29, RNA demethylases FTO and TYY517,30, DNA demethylase AlkB31,32, and DNA 5′-cytosine hydroxylases including Ten Eleven Translocase 233. Sequence alignments reveal how proteins are related evolutionarily, while structural comparisons validate or invalidate the accuracy of the sequence alignment. Our sequence alignment indicates that JMJD7 (residues from 27–294) is highly similar to JMJD5 (residues from 183–416) with 25.1% identity and 43.6% similarity (Fig. S3). Not surprisingly, the structure of JMJD7 overlays well with that of JMJD5 (residues 183–416, c-JMJD5) lacking the N-terminal domain, whose structure has been reported by numerous groups24,25 including our own (RSCB ID: 4QU1, Table S1). The RMSD is less than 2.0 Å (230 Cα, excluding two beta hairpins formed by β3 and β4 and β12 and β13) using the Dali program (http://ekhidna.biocenter.helsinki.fi/dali_server/) (Fig. 2C). The main difference between c-JMJD5 and JMJD7 is that JMJD7 has an extra two helix bundle and two extra beta hairpins, both of which may participate in dimer formation (Fig. 2C, Fig. S3). The most striking similarity between these two structures is the surface charge distribution; both contain concentrations of negative charge at the catalytic center (Fig. 2A, B). The structural similarity indicates common functional roles. We propose that both c-JMJD5 and JMJD7 recognize positively charged moieties including methylated arginine residues. However, significant differences in charge distribution near the catalytic center were also revealed; there are two flanking positive patches adjacent to the catalytic center on JMJD7, but not on c-JMJD5 (Fig. 2A, B).

JMJD6 has been reported to possess arginine demethylase activity toward both H3R2 and H4R34,5. Therefore, we examined whether structural similarities could be identified between JMJD6 (residues 120–334) and JMJD7/c-JMJD5. Overall, the differences are significant with RMSD of 3.3 Å (Fig. S4). Interestingly, we found similar negative charge distributions at the proteins’ catalytic centers, but dramatic differences in surrounding residues between JMJD6 and JMJD7/c-JMJD5 (Fig. S4). This analysis suggests that JMJD6 may recognize substrates that are similarly charged at the catalytic center, but have significantly different neighboring charge distributions relative to c-JMJD5 and JMJD7. This result is consistent with our early report that the catalytic core of JMJD6 (residues 1–334) barely binds to single strand RNA (ssRNA) though the entire JMJD6 (1–403) nonspecifically recognizes ssRNA with high binding affinity46, suggesting that ssRNAs are not substrates of JMJD6. However, it is possible that binding between JMJD6 and single stranded RNA may recruit JMJD6 to its actual substrate(s).

The complex structure of c-JMJD5 and a symmetric di-methyl arginine derivative. All JmjC domain containing proteins characterized to date have oxygenase activities19. The catalytic cores of both JMJD5

Figure 2. Comparisons of JMJD5 and JMJD7. (A) Structure and surface charge distributions of JMJD7. (B) Structure and surface charge distribution of JMJD5. All surface charges figures in the context were generated using PyMOL (Action > generate > vacuum electrostatics > protein contact potential) (https://pymol.org/2/). Red represents negatively-charged surface, Gray represents neutral-charged surface, and Blue represents positively-charged surface (contour level from negative charge −49.921 to positive charge + 49.921). Dotted green circle indicates the active site. Dotted yellow circle indicates uniquely positively-charged patches near JMJD7 active site. (C) The overlap of JMJD5 on JMJD7. Top- ribbon model. Bottom- surface charges.
and JMJD7 are structurally similar to other JmjC proteins. What structural features within c-JMJD5 and JMJD7 are responsible for the peptidase activities? As we previously reported, activities of c-JMJD5 and JMJD7 are dependent on divalent cations, similar to typical metalloproteases. Comparison of c-JMJD5 and JMJD7 structures to those of metalloproteases revealed that both c-JMJD5 and JMJD7 contain basic elements required for hydrolysis, such as similar residues chelating divalent ions (His321, Asp323, and His400 in JMJD5) and rich negatively charged sidechains as proton acceptor (Asp323 and imidic-Gln275 in JMJD5) within the catalytic center of JMJD5. We found that methylated arginines play critical roles in the recognition between JMJD5/7 and methylated histone tails. To investigate the basis of specific recognition and catalysis, we determined the complex structure of c-JMJD5 in the presence of a symmetric dimethyl arginine derivative (DM(s)-Arg), Zn2+ and α-KG. Zn2+ substitutes functionally for Fe2+ (see below) and is more stable than Fe2+ in solution. We found that the methyl groups of di-methyl arginine are buried in a negatively charged pocket consisting of one glutamic acid (Glu238), two tyrosines (Tyr243, Tyr272), two tryptophans (Trp248, Trp310), one Ser318, and a portion of α-KG. The carboxyl group is coordinated with Zn2+; this structure could mimic the final step of peptidase cleavage with the oxygen of the carbonyl interacting with Zn2+ (Fig. 3D). To cross-confirm the authenticity, we also determined the complex structure of c-JMJD5 and monomethyl arginine, and to no surprise, the monomethyl arginine occupies the exact same position as that of dimethyl arginine, except missing a methyl group (Fig. S6, Table S5, Table S6). It will be of interest to obtain a complex structure of c-JMJD5 and asymmetric dimethyl arginine, given that there is enough space to hold two methyl groups at either side based on the large pocket within c-JMJD5. However, we failed to obtain crystals of c-JMJD5 with asymmetric dimethyl arginine or c-JMJD5 with any short peptide containing methylated arginines thus far.

The catalytic mechanism of c-JMJD5 and c-JMJD7. All catalytic cores of JmjC proteins, or Fe2+ and α-KG dependent oxygenases, contain the highly conserved triple residues HXD/E(X)nH (X = any residue) to chelate Fe2+ (Fig. S3). This structural motif is highly similar to those of metallo-endopeptidases and metallo-exopeptidases. Adding EDTA or mutating the three Fe2+-chelating residues to Ala completely abolished the enzymatic activities of c-JMJD5. Interestingly, among metalloproteases, additional Glu, Asp, and His residues are required nearby for proton transfer, polarization, and nucleophilic attack of substrates. We hypothesized that the binding of α-KG by JmjC proteins may release some sidechains from three chelating residues and act as a part...
of a process similar to that enabled by electron rich residues in peptidases. In this regard, we tested the catalytic activities of c-JMJD5 and c-JMJD7 with and without α-KG. To avoid the contamination by α-KG, a point mutation of a critical α-KG binding lysine residue (Lys336) located at the bottom of the α-KG binding pocket (Fig. S5C, Fig. S6E) within c-JMJD5 to glutamic acid was generated. Interestingly, the mutation dramatically reduces the enzymatic activity of c-JMJD5 (Fig. 3F), suggesting that α-KG is essential for the catalytic activity of c-JMJD5.

For hydrolysis, only H₂O (and not O₂) is coordinated with divalent cations Fe²⁺ or Zn²⁺ in JmjC proteins and is polarized (Fig. 3C). We examined the sequences of JMJD5 and JMJD7 to investigate which residue is the intermediate proton acceptor during the catalysis process. We found that Gln275 in JMJD5 and Gln131 in JMJD7 are conserved and close to the catalytic center (Fig. 3C, Fig. S3). To test whether this residue is involved in the catalysis process, a point mutation of Gln275 to Ala was generated in c-JMJD5. The mutation nearly abolished the activity of c-JMJD5 (Fig. 3F). Although Gln275 is not a strong proton acceptor compared to Glu, Asp, or His, it may act as a proton acceptor during catalysis by c-JMJD5. Interestingly, several reports showed that amide-carbonyl groups of Gln and Asn can form an imidic acid to participate proton transferring under a special microenvironment. A question here is why JMJD5 possesses glutamine instead of glutamic acid at position 275. To investigate the functional contribution of Gln275, a point mutation of Gln275 to Glu275 was generated. To our surprise, the Glu275 mutation has a higher enzymatic activity (Fig. 3G). We speculate that lower Gln275 activity may be required for JMJD5 in vivo. However, additional evidence is needed to prove this speculation.

Specific binding between c-JMJD5/c-JMJD7 and substrates. The multiple reported activities of JMJD6 (e.g., lysine hydroxylase, arginine demethylase, and RNA demethylase) have raised questions concerning how this protein and related JmjC family members recognize cognate substrates. Mechanisms that control substrate specificity are crucial towards understanding the functions of these proteins. Each of these proteins include residues necessary for similar biochemical reactions (i.e., oxidation of carbon-nitrogen bonds). Here, we assess a common criterion of specific and non-specific substrate recognition: the binding affinity between enzyme and substrate. In our previous studies of JMJD2 family members and their cognate peptide substrates, we identified binding affinities in the range of ~1 to 10 μM. In preliminary experiments, we utilized bulk histones as substrates. Bulk histones are heterogeneous and theoretically contain most potential combinations of post-translational modifications. Thus, these substrates enable the detection of binding by different cognate enzymes. We immobilized bulk histones on a Biacore chip and injected the JmjC proteins to measure their binding affinity. We observed significant binding affinity of both c-JMJD5 and JMJD7 on bulk histones (due to non-linear binding kinetics, ranges of approximately 1–50 μM were estimated) (Fig. 4A, B).
experiments were introduced to resolve the exact binding constants between enzyme and substrates. The binding affinities of various lysine binding domains, such as Chromodomains, PHD fingers, Tudor domains, etc., to lysine residues with and without methylation has been very well established. It is also true that the difference in binding affinities of Tudor domains to arginine with and without methylation is also marginal. The question here is whether c-JMJD5 or JMJD7 has different binding affinity depending on the methylation status of arginine. From the complex structure shown above, c-JMJD5 contains a binding pocket for methylarginine that is similar to that of Tudor domains (Fig. 3D,E, Figs S5, S6). We reasoned that the rich aromatic environment in the binding pocket of c-JMJD5 could be sensitive enough for accurate binding affinity readout for both arginine containing peptides with and without methylation through fluorescence polarization experiments. This turned out to be true in our previous report, where we found that c-JMJD5 binds to native form pH3 peptide with a measurable binding affinity (~7 μM, to pH3R2me2a with surprisingly high affinity ~0.112 μM, or ~70 times that of pH3). This binding affinity is similar to those between PHD domains and methylated lysines (0.16–30 μM), but is more than one order of magnitude higher than affinities between Tudor domains and methylated arginines (~4 μM). Based on the complex structure, much higher binding affinity between c-JMJD5 and pH3R2me2a (~0.1 μM) versus Tudor domains and methylarginine containing peptides (~4 μM) can be explained by the presence of additional charge-charge interactions within the methylarginine binding pocket of c-JMJD5 contributed by α-KG and a sidechain of glutamic acid (Glu238) (Fig. 3D). Interestingly, as pointed out by one of our reviewers, the sidechain of Ser318 makes a hydrogen bond with NE atom of sidechain of methylarginine (Fig. 3D), the binding should also contribute to the high binding affinity. Most importantly, this unique hydrogen bond may also differentiate methylarginine from methyllysine. Further investigation is needed.

Our previously reported results showed that c-JMJD5 discriminates pH3R2me2a from pH3 by exhibiting a much higher binding affinity. Although the biochemical mechanism in which c-JMJD5 discriminates between methylated versus unmodified arginine is unknown, it was demonstrated using lysine with various methylation states to assert that the methyl-ρ hydrophobic interactions within the aromatic cage is responsible for the observed higher affinity among higher lysine methylation states compared to unmodified lysine or lower lysine methylation states. Pending further investigation, this explanation fits our observation that pH3R2me2a exhibits greater binding affinity, compared to pH3, within c-JMJD5’s aromatic cage as well. Taken together, the dramatic differences in binding affinity between c-JMJD5 and histone tails with or without arginine methylation further confirms that JMJD5 is more specific for sites with arginine methylation.

From Surface Plasmon Resonance binding assays, c-JMJD5 and JMJD7 seem to recognize different combinations of modification of histone tails (Fig. 4). To further confirm the results, two forms of peptides with additional methylation and acetylation respectively on the basis of original pH3R2me2a and pH4R3me2a were subjected to fluorescence polarization binding assays. As expected, c-JMJD5 does not bind to either pH3R2me2a or pH4R3me2a peptides with additional acetylation (pH3R2me2a + AC, pH4R3me2a + AC) (Fig. 5B,C), while JMJD7 binds them with affinities of 15.73μM and 13.45μM, respectively (Fig. 5G). On the other hand, c-JMJD5 binds to pH3R2Kme3 with a binding affinity of 9.97μM (Fig. 5D) while JMJD7 does not (Fig. 5H). These data suggest that JMJD5 and JMJD7 differentiate themselves from recognizing different combinations of modification of histone tails. This is also reflected by the different charge distribution around catalytic cores of both enzymes as showed in the structural section. However, we must be aware that all these data are generated from short peptides, they may not reflect actual situation of histone tails within nucleosomes in vivo.
et al. report, Shen et al. also reported the proteolytic activity of JMJD5. That report represents a strong vindication of our observations, given that at least two separate research groups independently discerned JMJD5’s role as a protease that specifically cleaves histone tails. Although the Shen et al. report is only limited to methyl-lysines on H3 tail as cleavage targets, this may reflect JMJD5’s potentially broad substrate specificity beyond just methylarginine. In our previous report, JMJD5 has slightly increased binding affinity toward H3K4 methylated peptide (pH3(me2), ~4 μM) versus native form H3 (pH3, ~7 μM). At the same time, Tudor domains can recognize both methylated arginines and lysines. Following this rationale, the Tudor-domain-like structure of JMJD5 should accommodate both methylated arginines and lysines as well. However, the hydrogen bond between NE atom of methylarginine and the sidechain of Ser318 could be critical for substrate discrimination. Nevertheless, further characterization is needed to determine whether JMJD5 and JMJD7 have similar binding affinities towards methylated arginines or lysines on other sites of histone tails.

An interesting evolutionary question concerns how a family of oxygenases can give rise to proteases with both metallo-endopeptidase and metallo-exopeptidase activities. According to established catalysis mechanisms of these enzyme families, Zn2+ ions in the nucleus is conducing for the activities of JMJD5 and JMJD7. However, because JmjC proteins possess conserved structures and cofactors, it remains intriguing as to how JMJD5 and JMJD7 evolved to perform proteolytic activities in higher eukaryotes. One possible explanation is that a functional switching mechanism is employed under hypoxic environments.

In addition to divalent cations chelating residues, all metallo-endopeptidases and metallo-aminopeptidases require additional residues for their complete enzymatic activities. From the structures of c-JMJD5 and JMJD7, we found that one glutamine residue in each enzyme (Gln131 in JMJD7 and Gln275 in JMJD5) is close to the catalytic center and likely plays a critical role as a proton transferring intermediate (Fig. 3C–F). The mutation of Gln275 to Ala nearly abolished the activity of c-JMJD5 while the mutation of Gln131 to Glu increases the activity of either c-JMJD5 or JMJD7, suggesting that the catalytic activities of the enzymes does not require electron exchange as observed in hydroxylation. We expect that the abundance of Zn2+ ions in the nucleus is conducing for the activities of JMJD5 and JMJD7. However, because JmjC proteins possess conserved structures and cofactors, it remains intriguing as to how JMJD5 and JMJD7 evolved to perform proteolytic activities in higher eukaryotes. One possible explanation is that a functional switching mechanism is employed under hypoxic environments.

![Figure 5](image_url) Fluorescence polarization anisotropy binding assays of c-JMJD5 and JMJD7 to different peptides. (A) The mixture of c-JMJD5 to a random peptide shows no binding. (B) The mixture of c-JMJD5 to pH3R2(me2a) with additional acetylation of all available lysine residues results in no binding (pH3R2 + AC). (C) The mixture of c-JMJD5 to pH4R3(me2a) with additional acetylation of all available lysine residues results in no binding (pH4R3 + AC). (D) The mixture of c-JMJD5 to pH3R2(me2a)K4(me3) peptide results in binding constant 9.97 ± 0.32 μM. (E) The mixture of JMJD7 to a random peptide shows no binding. (F) The mixture of JMJD7 to pH3R2(me2a) with additional acetylation of all available lysine residues results in binding constant 15.73 ± 2.14 μM (pH3R2 + AC). (G) The mixture of JMJD7 to pH4R3(me2a) with additional acetylation of all available lysine residues results in binding constant 13.45 ± 0.26 μM (pH4R3 + AC). (H) The mixture of JMJD7 to pH3R2(me2a)K4(me2) peptide results in no binding.
of c-JMJD5 (Fig. 3E). These data confirm the hypothesis that this residue is important for catalysis. However, we did not find similar structures in other JmjC proteins with defined hydroxylase activities. Therefore, we hypothesize that glutamines in JMJD5 and JMJD7 confer the proteolytic activities of JMJD5 and JMJD7. Although Gln275 is not a strong proton acceptor compared to Glu, Asp, or His, it was reported that the carboxamide of Asn could form imidic acid to participate in proton relay in hydrolases, as well as SIRT2 deacetylase family proteins.\(^{40-42}\) All JmjC proteins examined required \(\alpha\)-KG as a co-factor for catalysis in the hydroxylation process. For hydroxylation, \(\alpha\)-KG is converted to succinate with release of CO\(_2\). From the complex structure of c-JMJD5 and the methylated arginine derivative (Fig. 3), it is clear that \(\alpha\)-KG is not only involved in pocket formation, but also forms a salt bridge or hydrogen bond with the methylated guanidine group (Fig. 3D). \(\alpha\)-KG also participates in the chelation of Zn\(^{2+}\) ions (Fig. 3C). Loss of \(\alpha\)-KG binding due to a point mutation of lysine to glutamic acid also causes a huge loss of the activity of c-JMJD5. However, the exact roles of \(\alpha\)-KG in JMJD5 and JMJD7 are not clearly defined. \(\alpha\)-KG may participate directly in substrate binding, direct catalysis, or both. On the other hand, the joining of \(\alpha\)-KG to chelate divalent ions also reduce the close association of the sidechain Asp323 toward the divalent ion (Fig. 3C), which may confer the sidechain of Asp323 the role of proton acceptor during hydrolysis. Nevertheless, based on those information, we can propose a potential hydrolysis mechanism that includes the following steps (Fig. 6). First, the sidechain of methylated arginine docks at the negatively charged pocket with aromatic cage, bringing the carbonyl group of this residue within close proximity to Zn\(^{2+}\). Second, the coordination of basic elements of hydrolysis including, Zn\(^{2+}\), Gln275, and potentially Asp323 of the JmjC domain with \(\alpha\)-KG participates in pocket formation, but also participates in the coordination of basic elements of hydrolysis (Fig. 6). Third, rearrangement of these elements results in cleavage of the peptide bond (Fig. 3C and Fig. 6). Interestingly, replacement of Fe\(^{3+}\) with Zn\(^{2+}\) or Co\(^{2+}\) does not affect the activities of c-JMJD5 (Fig. S7).

Analysis of products after reactions of c-JMJD5 and JMJD7 with synthesized peptides, we found that c-JMJD5 and JMJD7 preferentially cleaved methylarginine residues, but also continued cleavage after the initially targeted residue and lysine residues.\(^6\) Thus, after the first excision, the enzyme continued to act as a progressive aminopeptidase, resulting in digestion of the remaining C-terminal peptide. The region around the catalytic cores of JMJD5 and JMJD7 contain an area with a relatively hydrophilic and negatively charged space that could accommodate methylated and positively charged residues (Fig. 3D). The binding properties of JMJD5 and JMJD7 are similar to those of PHD and Tudor domains, or other methylated lysine and arginine binding domains. After the first cleavage and with the N-terminal fragment juxtaposed with the catalytic core, any positively charged, neutral, or hydrophobic residue at the N-terminal of a C-terminal product will be a substrate after a minor positional movement and will be exposed to further cleavage.

\textit{In vitro} experiments are carried out under high concentrations of both enzymes and substrates, which may lead to artificial or non-specific results. In this regard, we must examine binding affinity to judge whether the enzyme and substrate is cognate or specific. Both c-JMJD5 and JMJD7 bind to bulk histone with moderate binding affinity ranges around ~1–10 \(\mu\)M (Fig. 4A,B) suggesting specific recognition between JMJD5/7 and bulk histone tails. Since a combination of histone tail modifications is a common phenomenon, we reasoned that other modifications such as acetylation and methylation of neighboring residues required for the binding of both enzymes. Interestingly, neither c-JMJD5 nor JMJD7 binds to H4R3 with acetylation at the N-terminus. More interestingly, JMJD7 binds to hyperacetylated pH4R3 and pH3R2, but c-JMJD5 does not. Additional methylation of H3R2 N-terminal tails of H3 is also a common phenomenon. Methylation on K4 (pH3R3K4me3) prevents the
carried out for JMJD5. All experiments are carried out at room temperature. Protein were then injected to calculate the binding affinity between peptide and JMJD7. Similar procedures were solved in PBS and coated onto a streptavidin coated SA chip (GE Healthcare). Different concentrations of JMJD7 in our experiment are listed in Table S7. For peptides, 2 μM synthetic peptide with C-terminal biotin was dissolved in coating buffer (50 mM sodium acetate [pH 5.0]) and coated onto a CM5 chip (GE Healthcare). Different concentrations of JMJD7 protein were then injected to calculate the binding affinity between peptide and JMJD7. Most importantly, c-JMJD5 prefers additional methylated histone tails while JMJD7 prefers additional acetylated histone tails.

Materials and Methods

Crystallization, Data Collection, structural determination, and refinement of JMJD5, MBP-JMJD7 and JMJD7. Both human version of c-JMJD5 and mouse version of JMJD7 are expressed and purified as previously reported. c-JMJD5 with and without dimethylarginine/monomethylarginine was crystallized by vapor diffusion in hanging drops with 0.1 M HEPES pH7.0, 8% PEG3350 at 8 °C with 1 mM α-KG and 1 mM Zn2+ added. For data collection, c-JMJD5 crystals were transferred to a cryo-protecting buffer (reservoir buffer supplemented with 20% glycerol) and frozen in liquid nitrogen. All data of c-JMJD5 with and without substrates used in structure solving and refinement were collected on a beam line 24-ID-E, APS, Argonne National Laboratory. Data were integrated and scaled using the HKL2000 suite of programs. Structural determination and refinement results are shown in Tables S1, S5, S6.

MBP-JMJD7 (20 mg/ml) (mouse JMJD7) was crystallized by vapor diffusion against 100 mM Citrate Sodium, 20% PEG 3350 (Hampton Research) at 4 °C. For data collection, MBP-JMJD7 crystals were flash frozen in liquid nitrogen and sent to a synchrotron. The native JMJD7 crystals diffracted to only 9–10 Å using a home light source, so further dehydration was performed by increasing the PEG concentration in the well reservoir. After dehydration, the crystallographic structure of JMJD7 was increased to 4.1 Å with the home light source. JMJD7 crystals were frozen in liquid nitrogen and sent to a synchrotron. All data used in structure solving and refinement were collected on a beam line 4.2.2 (MBC-ALS) at the Advanced Light Source (Berkeley, ALS, USA). Data collection statistics are shown in Table S2. Data were integrated and scaled with the XDS Program Package. Structural determination and refinement results are shown in Table S2.

mJMJD7 (generated from GST-mJMJD7 and affinity-tag removal, 10 mg/ml) was crystallized by vapor diffusion against 0.1 M MES monohydrate pH6.0, 10% PEG4000 at 4 °C. For data collection, mJMJD7 crystals were flash frozen in liquid nitrogen and sent to a synchrotron. All data used in structure solving and refinement were collected on beam line 4.2.2 (MBC-ALS) at the Advanced Light Source (Berkeley, ALS, USA). Data collection statistics are shown in Table S3.

Biacore binding of JMJD5 and JMJD7 to bulk histone or synthetic peptides. 10 μg/ml calf bulk histone was dissolved in coating buffer (50 mM sodium acetate [pH 5.0]) and coated onto a CM5 chip (GE Healthcare). Different concentrations of JMJD7 protein were then injected to calculate the binding affinity between bulk histone and JMJD7. Peptides were purchased from AnaSpec Inc. The sequence for the peptides used in our experiment are listed in Table S7. For peptides, 2 μg/ml synthetic peptide with C-terminal biotin was dissolved in PBS and coated onto a streptavidin coated SA chip (GE Healthcare). Different concentrations of JMJD7 protein were then injected to calculate the binding affinity between peptide and JMJD7. Similar procedures were carried out for JMJD5. All experiments are carried out at room temperature.

Fluorescence Polarization experiment. Given the known structure of JMJD5, where aromatic residues are present in close proximity to the binding pocket, the following tryptophan fluorescence assay was deemed suitable for characterizing various peptide binding activity. All the regular and methylated peptides were synthesized by AnaSpec Inc. 10 μM c-JMJD5/JMJD7 was titrated with and equilibrated with fixed concentrations of each peptide respectively, incubated at 25 °C for 30 min between each titration intervals, and subject to fluorescence measurement. The buffer used in the fluorescence quenching assay was 20 mM Tris-HCl pH 6.5. The excitation wavelength of 280 nm and the emission wavelength of 342 nm was used for data collection and recorded with a Fluoromax-3 spectrometer. The titration samples were prepared and analyzed in parallel between 2 to 4 times. All values at different titration points were compiled, normalized against the maximum value obtained prior to titration and averaged. The error bars indicate the normalized minimum and maximum values at any given titration point. The Kd for each peptide was calculated by fitting to a 4 parameter sigmoidal dose-response curve with SigmaPlot v11.0.

Enzymatic assays with Radiolabeling of bulk histone with PRMTs using 14C-SAM. Overall, all activity assays of mutated versions of c-JMJD5 and JMJD7 follow the similar procedures as reported. Briefly, bulk histone treated with PRMTs were used as substrates for mutated c-JMJD5 and JMJD7. After the reaction, the
sample was separated by SDS-PAGE gel, which was then dried using a vacuum pump. The $^{14}$C radioactive signal was detected using a Typhoon 9500 imager (GE Healthcare).

**References**

1. Allis, C. D., Bowen, J. K., Abraham, G. N., Glover, C. V. & Gorovsky, M. A. Proteolytic processing of histone H3 in chromatin: a physiologically regulated event in Tetrahymena micronuclei. *Cell* **20**, 55–64 (1980).

2. Commerford, S. L., Carsten, A. L. & Cronkite, E. P. Histone turnover within nonproliferating cells. *Proc Natl Acad Sci USA* **79**, 1163–5 (1982).

3. Di Lorenzo, A. & Bedford, M. T. Histone arginine methylation. *FEBS Lett* **585**, 2024–31 (2011).

4. Chang, B., Chen, Y., Zhao, Y. & Bruick, R. K. JMJD6 is a histone arginine demethylase. *Science* **318**, 444–7 (2007).

5. Liu, W. et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. *Cell* **155**, 1581–95 (2013).

6. Walport, L. J. et al. Arginine demethylation is catalysed by a subset of JMJC histone lysine demethylases. *Nat Commun* **7**, 11974 (2016).

7. Weber, C. M., Ramachandran, S. & Henikoff, S. Nucleosomes are context-specific, H2A.Z-modulated barriers to RNA polymerase. *Mol Cell* **53**, 819–30 (2014).

8. Liu, H. et al. Clipping of arginine-methylated histone tails by JMJD5 and JMJD7. *Proc Natl Acad Sci USA* **114**(37) E7717–E7726 (2017).

9. Koster, M. J., Snel, B. & Timmers, H. T. Genesis of chromatin and transcription dynamics in the origin of species. *Cell* **161**, 724–36 (2015).

10. Zhou, Q., Li, T. & Price, D. H. RNA polymerase II elongation control. *Nat Rev Mol Cell Biol* **18**, 513–22 (2017).

11. Simmons, J. M., Muller, T. A. & Hausinger, R. P. Fe(II)/alpha-ketoglutarate hydroxylases involved in nucleobase, nucleoside, nucleotide, and chromatin metabolism. *Dalton Trans*, 5132–42 (2008).

12. Johansson, C. et al. The roles of jumonji-type oxygenases in human disease. *Epigenomics* **6**, 89–120 (2014).

13. Kloese, R. J. & Zhang, Y. Regulation of histone methylation by demethylimation and demethylation. *Nat Rev Mol Cell Biol* **8**, 307–18 (2007).

14. Shi, Y. Histone lysine demethylases: emerging roles in development, physiology and disease. *Nat Rev Genet* **8**, 829–33 (2007).

15. Hong, X. et al. Interaction of JMJD6 with single-stranded RNA. *Proc Natl Acad Sci USA* **107**, 14568–72 (2010).

16. Ka, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat Chem Biol* **7**, 885–7 (2011).

17. Kohli, R. M. & Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. *Nature* **502**, 472–9 (2013).

18. Hsiia, D. A. et al. KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. *Proc Natl Acad Sci USA* **107**, 9671–6 (2010).

19. Oh, S. & Janknecht, R. Histone demethylase JMJD5 is essential for embryonic development. *Biochem Biophys Res Commun* **420**, 61–5 (2012).

20. Wang, H. J. et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism. *Proc Natl Acad Sci USA* **111**, 279–84 (2014).

21. Zhu, H., Hu, S. & Baker, J. JMJD5 regulates cell cycle and pluripotency in human embryonic stem cells. *Stem Cells* (2014).

22. Ishimura, A. et al. JMJD5, an H3K36me2 histone demethylase, modulates embryonic cell proliferation through the regulation of Cdk1ca expression. *Development* **139**, 749–59 (2012).

23. Del Rizzo, P. A., Krishnan, S. & Trievel, R. C. Crystal structure and functional analysis of JMJD3 indicate an alternate specificity and function. *Mol Cell Biol* **32**, 4044–52 (2012).

24. Wang, H. et al. Structure of the JmJ-C-domain-containing protein JMJD5. *Acta Crystallogr D Biol Crystallogr* **69**, 1191–20 (2013).

25. Liu, Y. et al. Crystal structure of the SarK protein from Staphylococcus aureus. *Proc Natl Acad Sci USA* **98**, 6877–82 (2001).

26. Dann, C. E. III, Bruick, R. K. & Deisenhofer, J. Structure of factor-inhibiting hypoxia-inducible factor-1α: An asparaginyl hydroxylase. *Proc Natl Acad Sci USA* **75**, 10818–23 (2008).

27. Kelly, M. et al. Structural insights into histone demethylation by JMJD2 family members. *Cell* **125**, 691–702 (2006).

28. Chen, Z. et al. Structural basis of the recognition of a methylated histone tail by JMJD2A. *Proc Natl Acad Sci USA* **104**, 10818–23 (2007).

29. Kato, M. et al. Crystal structure of a novel JmJ-C-domain-containing protein, TYW5, involved in tRNA modification. *Nucleic Acids Res* **39**, 1576–85 (2011).

30. Aas, P. A. et al. Human and bacterial oxidative demethylases repair alklyation damage in both RNA and DNA. *Nature* **421**, 859–63 (2003).

31. Treweck, S. C., Henschaw, T. F., Hausinger, R. P., Lindahl, T. & Sedgwick, B. Oxidative demethylation by Escherichia coli AlkB directly reverts DNA base damage. *Nature* **419**, 174–8 (2002).

32. Hu, L. et al. Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. *Cell* **155**, 1545–55 (2013).

33. Rawlings, N. D. & Barrett, A. J. Evolutionary families of metalloenzyme. *Methods Enzymol* **248**, 183–228 (1995).

34. Musselman, C. A. & Kutateladze, T. G. Handicapping epigenetic marks with PHD fingers. *Nucleic Acids Res* **39**, 9061–71 (2011).

35. Migliori, V. et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. *Nat Struct Mol Biol* **19**, 136–44 (2012).

36. Tripsianes, K. et al. Structural basis for dimethylarginine recognition by the Tudor domains of human SMN and SF3B proteins. *Nat Struct Mol Biol* **18**, 1414–20 (2011).

37. Liu, H. et al. Structural basis for methylarginine-dependent recognition of Aubergine by Tudor. *Genes Dev* **24**, 1876–81 (2010).

38. Liu, K. et al. Structural basis for recognition of arginine methylated PIwi proteins by the extended Tudor domain. *Proc Natl Acad Sci USA* **107**, 18398–403 (2010).

39. Abbott, D. W., Macauley, M. S., Vocadlo, D. J. & Boraston, A. B. Streptococcus pneumoniae endohexosaminidase D, structural and mechanistic insight into substrate-assisted catalysis in family 85 glycoside hydrolases. *J Biol Chem* **284**, 11676–89 (2009).

40. Nakamura, A. et al. "Newton's cradle" proton relay with amide-imidic acid tautomerization in inverting cellulase visualized by neutron crystallography. *Sci Adv* **1**, e1500263 (2015).

41. Lee, L., Chen, Z. & Zhang, G. Catching Sir2-intermediates One Structure at the Time. *Cell Biol Chem* **24**, 248–249 (2017).

42. Bottger, A., Islam, M. S., Chowdhury, R., Schofield, C. J. & Wolf, A. The oxygenase JmjD–a case study in conflicting assignments. *Biochem J* **468**, 191–202 (2015).

43. Molina-Serrano, D., Schiza, V. & Kirmizis, A. Cross-talk among epigenetic modifications: lessons from histone arginine methylation. *Biochem Soc Trans* **41**, 751–9 (2013).

44. Ramon-Masqués, S. et al. The plant homeodomain finger of RAG2 recognizes histone H3 methylated at both lysine-4 and arginine-2. *Proc Natl Acad Sci USA* **104**, 18893–8 (2007).

45. Matthews, A. G. et al. RAG2 PHD finger couples histone H3 lysine 4 trimethylation with V(D)J recombination. *Nature* **450**, 1106–10 (2007).
47. Musselman, C. A., Lalonde, M. E., Cote, J. & Kutateladze, T. G. Perceiving the epigenetic landscape through histone readers. Nat Struct Mol Biol 19, 1218–27 (2012).
48. Li, H. et al. Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature (2006).
49. Shen, J. et al. JMJD5 cleaves monomethylated histone H3 N-tail under DNA damaging stress. EMBO Rep 18, 2131–2143 (2017).
50. Wang, Y. et al. Deacylation Mechanism by SIRT2 Revealed in the 1′-SH-2′-O-Myristoyl Intermediate Structure. Cell Chem Biol 24, 339–345 (2017).
51. Otwinowski, Z., Borek, D., Majewski, W. & Minor, W. Multiparametric scaling of diffraction intensities. Acta Crystallogr A 59, 228–34 (2003).
52. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr D Biol Crystallogr 66, 133–44 (2010).

Acknowledgements

We thank the Howard Hughes Medical Institute, the Zuckerman/Canyon Ranch, and Alan Lapporte for supporting our x-ray and computing facilities; Gina Clayton, Frances Crawford, Desiree Straign, Abbey Esbenson, Ryan Walsh, and other researchers at National Jewish Health (NJH) for their kind support. All data sets of JMJD7 were collected from Molecular Biology Consortium Beamlines 4.2.2 at the Advanced Light Source (Berkeley, CA). Data set of c-JMJD5 was collected at the beam line 24-ID-E, APS, Argonne National Laboratory. H.L. is partially supported by HHMI, NIH AI1109219 (to G.Z.), and NIH Training grant ST32AI074491-07 (to J. C.). S.L. is supported by NIH Training Grant T32AI007405-27 (to P. M.). J.H. was supported by NIH grants AI081878, AI115696, and by the Gift of Life Bone Marrow Foundation—in Honor of Wendy Siegel. P.M. and J.K. are supported by HHMI. C.W. and G.Z. were partially supported by NIH AI12295 (to P. M.), AI115696 (to J.H. and G.Z.), AI109219 (to G.Z.).

Author Contributions

G.Z. conceived the story and wrote up the manuscript. H.L., C.W., S.L., and G.Z. designed and carried out most of the experiments and data analysis. F.N., Y.W., Q.Z., Z.C., J.Z., J.N., S.D. carried out some experiments. P.M., J.H., and J.K. designed some experiments.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-21432-8.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018